Tara B. Manion
Pfizer (United States)(US)Creative Research Enterprises (United States)(US)
Publications by Year
Research Areas
Lipid metabolism and biosynthesis, Vector-borne infectious diseases, Pancreatic function and diabetes, Adipose Tissue and Metabolism, Viral Infections and Vectors
Most-Cited Works
- → Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1(2011)102 cited
- → Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans(2013)37 cited
- → Modeling the Mechanism of Action of a DGAT1 Inhibitor Using a Causal Reasoning Platform(2011)34 cited
- → ViableBorrelia Burgdorferiin the Urine of Two Clinically Normal Horses(1998)17 cited
- → In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity(2007)16 cited
- → Sustained In Vivo Activity of Recombinant Bovine Granulocyte Colony Stimulating Factor (rbG-CSF) Using HEPES Buffer(2001)14 cited
- → Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide(2011)12 cited
- → Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion(2017)8 cited
- Lyme Disease in Horses: Serological and Antigen Testing Differences(1998)
- → Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents(2006)8 cited